Avacincaptad Pegol in Geographic Atrophy from Age-related Macular Degeneration

This study focuses on individuals with a condition called geographic atrophy, which is a severe form of age-related macular degeneration (AMD). AMD affects the macula, the part of the retina responsible for clear central vision, leading to vision deterioration. Geographic atrophy involves the gradual loss of cells in the retina, potentially resulting in permanent vision loss. The study aims to better understand how avacincaptad pegol, a treatment approved in the U.S. to slow the progression of this condition, is used in real-world clinical settings. By gathering information on treatment patterns and any medical issues related to avacincaptad pegol, researchers hope to improve care for individuals with this challenging eye condition. Participants in the study will receive their usual eye examinations as part of routine care, and their doctors will prescribe avacincaptad pegol if they deem it appropriate. This is an observational study, meaning it collects data without influencing treatment decisions. Information about the frequency and dosage of avacincaptad pegol injections, as well as the duration and reasons for stopping treatment, will be gathered from medical records. Participants will also complete surveys about their eye health when they start the treatment and periodically for up to five years. These surveys will help track any changes in their condition and the impact of the treatment over time.